CLK8 (25 mg/kg; a single i.p.) decreases CLOCK levels in whole cell lysates of the mouse livers, whereas the levels of BMAL1 and CRY1 are unaltered[1].
CLK8 (5-1000 mg/kg; i.p.) exhibits no mortality or clinical signs (dyspnea, hyporeflexia, reduced locomotor activity, piloerection, hunched posture, and corneal opacity) at the doses of 5 and 25 mg/kg[1].
| Animal Model: | Male C57BL/6J mice (8 weeks, 18-24 g)[1] |
| Dosage: | 25 mg/kg |
| Administration: | A single i.p. |
| Result: | A decrease in CLOCK levels was detected in whole cell lysates of the mouse livers, whereas the levels of BMAL1 and CRY1 were unaltered.
Decreased the abundance of CLOCK in the nucleus.
The abundances of cytosolic and nuclear BMAL1 and CRY1 were unaltered.
Decreased Cry1 transcriptional level.
|
![2-[[2-[(8,8-dimethyl-2-oxo-4-phenyl-9,10-dihydropyrano[2,3-h]chromen-5-yl)oxy]acetyl]amino]benzamide Structure](/CAS/20180723/GIF/898920-65-5.gif)
